In this work, we show that this PgR-based estradiol-challenge test, as an in vivo assessment of tumor ER functional status, would be a much stronger predictor of benefit from ET than the mere presence of ER and/or PgR by IHC in a biopsy sample of a single lesion. This evidence concerns the gene PGR and neoplasm.